Literature DB >> 20221704

Clinical presentation, staging and long-term evolution of parathyroid cancer.

Nadia Talat1, Klaus-Martin Schulte.   

Abstract

BACKGROUND: Parathyroid cancer is rare and often fatal. This review provides an in-depth analysis of 330 clinical cases reported in detail. These data are used to inform a proposal for a hitherto lacking TNM staging system.
MATERIALS AND METHODS: All case reports or series with sufficient case details of parathyroid cancer were identified from PubMed, and data were analyzed using SPSS.
RESULTS: Of 330 patients, 117 (35%) died of disease and 207 (63%) experienced recurrence in a total of 2007 follow-up years and a mean length of follow-up of 6.1 years. Histopathology findings rather than biochemical or clinical features predict outcome. In univariate analysis, survival and recurrence rates are significantly influenced by gender (male relative risk [RR] 1.7, 95% confidence interval [95% CI] 1.0-2.7, P < .01), and presence of vascular invasion (RR 4.3, 95% CI 1.1-17.7, P < .01), or lymph node metastases (RR 6.2, 95 %CI 0.9-42.9, P < .001). Failure to perform oncological surgery carries a high risk for recurrence and death (local versus en bloc resection RR 2.0, CI 1.2-3.2, P < .01) as for redo surgery. Staging by a novel anatomy-based TNM system identifies significant outcome variation as to recurrence and death. Separation of patients into low and high risk identifies a 3.5-7.0 fold higher risk of recurrence and death (P < .01) for the high-risk group. Distant metastases predominantly target mediastinum and lung.
CONCLUSION: Understaging and undertreatment are shown to contribute to high recurrence rates and death toll. To improve outcome, en bloc resection including central lymph node dissection should be the minimal surgical approach in any patient with suspected parathyroid cancer.

Entities:  

Mesh:

Year:  2010        PMID: 20221704     DOI: 10.1245/s10434-010-1003-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  39 in total

1.  Lymph node involvement and surgical approach in parathyroid cancer.

Authors:  Klaus-Martin Schulte; Nadia Talat; John Miell; Caje Moniz; Prakash Sinha; Salvador Diaz-Cano
Journal:  World J Surg       Date:  2010-11       Impact factor: 3.352

2.  Multiple brown tumours from parathyroid carcinoma.

Authors:  Daryl Jade Tardo Dagang; Jerico Baliton Gutierrez; Mark Anthony Santiago Sandoval; Frances Lina Lantion-Ang
Journal:  BMJ Case Rep       Date:  2016-06-29

Review 3.  Association of parathyroid carcinoma and thyroid disorders: A clinical review.

Authors:  Alfredo Campennì; Salvatore Giovinazzo; Salvatore Antonio Pignata; Francesca Di Mauro; Domenico Santoro; Lorenzo Curtò; Francesco Trimarchi; Rosaria Maddalena Ruggeri; Sergio Baldari
Journal:  Endocrine       Date:  2016-10-15       Impact factor: 3.633

4.  Is central lymph node dissection necessary for parathyroid carcinoma?

Authors:  Kun-Tai Hsu; Rebecca S Sippel; Herbert Chen; David F Schneider
Journal:  Surgery       Date:  2014-11-11       Impact factor: 3.982

5.  Ultrasound features of malignancy in the preoperative diagnosis of parathyroid cancer: a retrospective analysis of parathyroid tumours larger than 15 mm.

Authors:  Paul S Sidhu; Nadia Talat; Preena Patel; Nicola J Mulholland; Klaus-Martin Schulte
Journal:  Eur Radiol       Date:  2011-05-10       Impact factor: 5.315

6.  [Surgical therapy of lung metastases from head and neck cancer].

Authors:  S Macherey; S F Preuss; F Doerr; S Grönke; M Heldwein; A Quaas; T Zander; K Hekmat
Journal:  HNO       Date:  2014-12       Impact factor: 1.284

7.  Parathyroid carcinoma, a rare cause of primary hyperparathyroidism.

Authors:  Adam Alperstein; Rajendra Bhayani
Journal:  BMJ Case Rep       Date:  2014-08-19

Review 8.  Non-functional parathyroid carcinoma: a case report and review of the literature.

Authors:  Liang Wang; Dali Han; Wanjun Chen; Shuguang Zhang; Zhiqi Wang; Ke Li; Yongsheng Gao; Shujuan Zou; Aiju Yang
Journal:  Cancer Biol Ther       Date:  2015-09-25       Impact factor: 4.742

9.  Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer.

Authors:  Peter P Truran; Sarah J Johnson; Richard D Bliss; Thomas W J Lennard; Sebastian R Aspinall
Journal:  World J Surg       Date:  2014-11       Impact factor: 3.352

Review 10.  Update on parathyroid carcinoma.

Authors:  F Cetani; E Pardi; C Marcocci
Journal:  J Endocrinol Invest       Date:  2016-03-21       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.